CN112618922A - Preparation method of drug balloon, prepared drug balloon and application thereof - Google Patents
Preparation method of drug balloon, prepared drug balloon and application thereof Download PDFInfo
- Publication number
- CN112618922A CN112618922A CN202011609609.0A CN202011609609A CN112618922A CN 112618922 A CN112618922 A CN 112618922A CN 202011609609 A CN202011609609 A CN 202011609609A CN 112618922 A CN112618922 A CN 112618922A
- Authority
- CN
- China
- Prior art keywords
- drug
- balloon
- coating
- medicine
- printing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/10—Processes of additive manufacturing
- B29C64/106—Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
- B29C64/118—Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
- A61M2025/1031—Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Abstract
The invention discloses a preparation method of a medicine balloon, which comprises the following steps: step 1, designing a three-dimensional model of a balloon body and a drug coating of a drug balloon by using modeling software, and importing a print file of the three-dimensional model into a printer; step 2, adding a printing material of the drug coating into the printer, and printing a first drug coating according to the printing file; and 3, connecting and fixing the balloon body and the first medicine coating. According to the medicine balloon prepared by the preparation method disclosed by the invention, the medicine coating can be uniformly and firmly fixed on the surface of the balloon body, so that the rush-off of the medicine in the in-vivo conveying process is reduced, and the utilization rate of the medicine is improved; the preparation method is accurate, stable and efficient, is suitable for industrial mass production, and has wide application prospect.
Description
Technical Field
The invention relates to the technical field of drug balloons, in particular to a preparation method of a drug balloon, the prepared drug balloon and application thereof.
Background
Vascular stenosis is a common disease in the clinic. The blood vessel stenosis is easy to cause unsmooth blood flow of the blood vessel, and even can block the blood vessel to cause life danger in serious cases. The current major treatment for vascular stenosis involves placement of a vascular stent and delivery of medication via a drug balloon.
The invention of the stent provides a better solution for solving atherosclerosis and intravascular stenosis, so that the treatment efficiency is greatly improved, but the restenosis in the blood vessel and the stent occurs at the same time, and the invention has the defects of not ideal treatment effect on small blood vessels, branched blood vessels, in-situ lesions and the like.
Drug balloons can be used to address restenosis. The treatment scheme of the medicine balloon is essentially derived from the concept of a local medicine conveying device based on a catheter, the medicine carried by the balloon inhibits intimal hyperplasia, and when the balloon is conveyed to a diseased blood vessel wall and is stretched, expanded and contacted with the blood vessel wall intimal, the medicine is quickly released and transferred into the local blood vessel wall by tearing the blood vessel wall intimal and pressurizing. The medicine has local effect of resisting vascular intimal hyperplasia, so as to prevent vascular restenosis after vascular intervention.
Patent CN106798951A discloses a preparation method of a drug eluting balloon, comprising the following steps: soaking the saccule in inorganic salt water solution for 1-1.5 hours, taking out and drying; adding water into the medicine solution, stirring uniformly, and standing for 1-2 minutes; and immersing the dried saccule in the medicine solution for 1-2 hours, taking out the saccule and drying to obtain the medicine eluting saccule. Wherein the inorganic salt aqueous solution is a sodium chloride-magnesium chloride mixed aqueous solution or a calcium chloride-magnesium chloride mixed aqueous solution; the drug solution consists of a drug, an additive and a solvent. The invention utilizes mixed inorganic salt aqueous solution to promote the obtaining of smaller drug crystal particles and increase the bonding force between the drug and the balloon. However, the drug coating by dip coating causes uneven distribution and poor fastness of the drug coating. Patent CN106267377A discloses a drug-coated balloon catheter, the drug coating comprising an active drug and a carrier; the active drug is paclitaxel, rapamycin, a paclitaxel derivative or a rapamycin derivative; the carrier includes an organic acid salt and a polyol. The organic acid salt and the polyhydric alcohol in the drug coating layer play a role together, and the particle size of drug particles is small, so that the drug is prevented from being released prematurely before the balloon catheter is placed into a target site. However, the drug coating is attached to the surface of the balloon only by simple coating, and the problem that the drug coating is washed off during in vivo delivery cannot be avoided. Patent CN106237485A discloses a preparation method of a drug-coated balloon dilatation catheter: the drug with the carrier is firstly sprayed on the surface of the balloon, and then a water-soluble protective layer is coated on the surface of the balloon. The medicine balloon obtained by the preparation method reduces the loss of the balloon in the conveying process to a certain extent, but also prevents the medicine from being released after the medicine reaches the lesion part, so that the medicine cannot effectively enter tissue blood vessels.
Therefore, the technical personnel in the field aim to design a preparation method of the drug balloon, the prepared drug balloon and the application thereof, so that the drug of the drug coating is uniformly distributed, can be firmly combined on the surface of the balloon body, and is beneficial to drug release and adsorption on the blood vessel wall.
Disclosure of Invention
In view of the above defects in the prior art, the technical problem to be solved by the present invention is to achieve uniform drug distribution of the drug coating, to enable the drug coating to be firmly bonded to the balloon surface, and to facilitate drug release and adsorption on the blood vessel wall.
In order to achieve the above object, the present invention provides a method for preparing a drug balloon, comprising the steps of:
step 1, designing a three-dimensional model of a balloon body and a drug coating of a drug balloon by using modeling software, and importing a print file of the three-dimensional model into a printer;
and 2, adding the printing material of the medicine coating into the printer, and printing out a first medicine coating according to the printing file.
Further, the step 2 adopts a 3D printing technology for printing.
Further, the 3D printing technique includes at least a fused deposition modeling technique.
Further, the method further comprises connecting a fixation balloon body with the first drug coating.
Optionally, the balloon body and the first drug coating are connected and fixed by adopting a light fixing method.
Optionally, the material of the drug coating further comprises a photoinitiator configured to fixedly couple the balloon body with the first drug coating.
Alternatively, ultraviolet rays are used as the catalyst.
Further, the lower surface of the first drug coating wraps the outer surface of the balloon body.
Further, the material of the drug coating includes an active drug and a carrier.
Optionally, the material of the drug coating further comprises a biodegradable material.
Optionally, the biodegradable material at least comprises one or more of polylactic-co-glycolic acid (PLGA), polylactic acid (PLA), Polycaprolactone (PCL).
Further, the carrier at least comprises one or more of inorganic salt and polyhydric alcohol.
Further, the invention also discloses a medicine balloon obtained by the preparation method of the medicine balloon.
Optionally, the first drug coating of the drug balloon comprises a first substrate, a lower surface of the first substrate is connected with the outer surface of the balloon body, and an upper surface of the first substrate has a protruding structure.
Optionally, the projection comprises an array of microneedles.
Optionally, the microneedle array is uniformly distributed on the first substrate.
Optionally, the material of the microneedle array comprises at least a photocrosslinker and the material of the first substrate comprises at least a photoinitiator.
Further, the invention also discloses application of the medicinal balloon as described above in treating intravascular stenosis or restenosis.
Compared with the prior art, the invention has the beneficial technical effects that:
1) by adopting a 3D fused deposition modeling printing technology, all components (such as active drugs, carriers, photoinitiators and the like) of the drug coating are distributed more uniformly, and particles are smaller;
2) the drug coating and the balloon body are fixed by adopting a light fixing method, so that the connection is firmer, and the fixing agent has no harmful components;
3) adopt the micropin array, more be favorable to the drug release and adsorb on the vascular wall, and can cooperate the expansion forced induction to trigger the mode, in the vascular wall is embedded in the transmission of active medicine or active medicine granule, reduce the loss of medicine.
The conception, the specific structure and the technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, the features and the effects of the present invention.
Drawings
Fig. 1 is an enlarged schematic view of a partial structure of a drug balloon according to a preferred embodiment of the present invention.
Detailed Description
The technical contents of the preferred embodiments of the present invention will be more clearly and easily understood by referring to the drawings attached to the specification. The present invention may be embodied in many different forms of embodiments and the scope of the invention is not limited to the embodiments set forth herein.
In the drawings, structurally identical elements are represented by like reference numerals, and structurally or functionally similar elements are represented by like reference numerals throughout the several views. The size and thickness of each component shown in the drawings are arbitrarily illustrated, and the present invention is not limited to the size and thickness of each component. The thickness of the components may be exaggerated where appropriate in the figures to improve clarity.
The drug balloon was prepared in this example by the following method:
step 1, designing a three-dimensional model of a balloon body and a drug coating of a drug balloon by using modeling software, and importing a print file of the three-dimensional model into a printer;
step 2, adding a printing material of the drug coating into the printer, and printing a first drug coating according to the printing file;
and 3, connecting and fixing the balloon body and the first medicine coating.
To improve the drug distribution uniformity of the first drug coating, optionally, printing is performed using 3D printing techniques. Further optionally, 3D printing techniques using fused deposition modeling are employed. When the first medicine coating is printed by fused deposition molding, firstly heating and melting a printing material in a spray head, then controlling the spray head to move along a set section profile and a filling track, and extruding the molten printing material; the printing material is rapidly solidified after the outlet and is bonded with the surrounding printing material, so that each layer sheet is formed by stacking on the upper layer, and the uniformity of medicine distribution is improved.
The core of the drug balloon and serving the therapeutic function is the drug coating. The antiproliferative drugs acting on the drug coating are generally lipophilic drugs, are insoluble in water, and are easily agglomerated to form microparticles. In the actual implantation process of the medicine sacculus, the medicine coating can be washed away by blood flow, the medicine coating can be dissolved by blood, and the blood vessel wall inevitably rubs with the medicine sacculus mutually. If the number of the exfoliated microparticles is large, the amount of drug reaching the target blood vessel is reduced, and on the other hand, the exfoliated microparticles easily cause complications such as distal vascular occlusion and thrombus, and serious amputation may result. Therefore, in order to improve the firmness of the drug coating, the first drug coating and the balloon body are fixedly connected by the fixing agent.
The balloon body is typically a biomaterial, the active drug is also typically lipophilic, and the drug balloon is typically inside the blood vessel. Therefore, the balloon body and the drug coating must ensure that the materials used are not medically toxic. Meanwhile, considering that the temperature of the production process and the exposure time in the outside can affect the activity and the purity of the medicine, optionally, the fixing balloon body and the first medicine coating are connected by adopting an optical fixing method so as to reduce the use and the residue of the fixing agent. Further optionally, ultraviolet light is used for irradiation, so that the first medicine coating is connected and fixed with the outer surface of the balloon body more quickly.
Accordingly, in order to match the photo-fixation method or the ultraviolet light fixation method, the material of the first drug coating layer at least comprises an active drug, a carrier, a photocrosslinking agent or a photoinitiator.
Further optionally, the carrier material may include an inorganic salt or polyol to facilitate smaller active drug crystal particles, thereby increasing the bonding force of the first drug coating to the balloon body.
Optionally, the first drug coating layer may further include a biodegradable material, and the biodegradable material at least includes one or more of poly (lactic-co-glycolic acid) (PLGA), poly (lactic acid) (PLA), and Polycaprolactone (PCL).
In addition, factors affecting the efficacy of drug coatings include: 1) the ability of the active agent to be released from the drug coating into the vessel wall; 2) the ability of the active agent to enter the endothelial tissue after reaching the vessel wall; 3) and resistance to blood wash when not absorbed by the tissue. This corresponds to the active drug release rate of the drug coating, the penetration capacity of the active drug, and the retention capacity of the drug coating on the vessel wall, respectively.
In the invention, the upper surface of the first drug coating is provided with a protruding structure so as to improve the holding capacity between the drug balloon and the vessel wall and increase the release capacity of active drugs. Specifically, the drug coating includes a first substrate having a protruding microneedle array on an upper surface thereof.
Fig. 1 is a schematic structural diagram of a drug balloon according to a preferred embodiment of the present invention, which includes a balloon body 1, a first substrate 2 and a microneedle array 3; the first substrate 2 and the microneedle array 3 form the first drug coating; the lower surface of the first substrate 2 wraps and winds the outer surface of the balloon body 1, and the upper surface of the first substrate 2 is provided with a microneedle array 3.
Further optionally, the microneedle array comprises an active pharmaceutical ingredient. The micro-needle type protrusions facilitate the micro-needle array to be adsorbed on the blood vessel wall more deeply, thereby increasing the retention capacity on the blood vessel wall and the penetration capacity of the medicine.
Optionally, the protruding structure may also be selected from a hemispherical shape, a block shape, and a circular truncated cone shape.
Corresponding to the first substrate with the microneedle array, the step 2 is further refined into the following steps:
2.1, adding a printing material required by the first substrate into a printer, and printing the first substrate by utilizing a fused deposition modeling 3D printing technology;
the material of the first substrate comprises a photocrosslinking agent and a second biodegradable material, wherein the photocrosslinking agent at least comprises one or more of chitosan and acrylic resin, and the second biodegradable material at least comprises one or more of polylactic-co-glycolic acid (PLGA), polylactic acid (PLA) and Polycaprolactone (PCL);
2.2, adding a printing material required by the microneedle array into a printer, controlling the position of a nozzle on the first substrate, and printing the microneedle array on the first substrate by using a fused deposition modeling 3D printing technology to fix the microneedle array on the substrate;
the material of the microneedle array comprises an active drug, a carrier, a photoinitiator and a first biodegradable material, wherein the first biodegradable material at least comprises one or more of polylactic-co-glycolic acid (PLGA), polylactic acid (PLA) and Polycaprolactone (PCL).
The first substrate is disposed of a different material than the microneedle array such that the active agent is concentrated on the microneedle array, thereby increasing the release rate of the active agent.
In addition, can also cooperate sacculus expansion pressure induction to trigger the mode, in the embedding vascular wall is launched to active medicine or active medicine granule, reduce the loss of active medicine.
Corresponding to the ultraviolet light fixing method, the step 3 specifically includes:
and wrapping the lower surface of the first substrate on the balloon body for a circle, and then placing the balloon body under ultraviolet light to trigger the fixation effect to obtain the medicine balloon.
The invention also discloses the drug balloon, which has high firmness and uniformity of drug coating, is beneficial to the release of active drugs, and can be applied to the treatment of intravascular stenosis or restenosis.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations could be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the prior art according to the concept of the present invention should be within the scope of protection defined by the claims.
Claims (10)
1. A method of making a drug balloon, the method comprising the steps of:
step 1, designing a three-dimensional model of a balloon body and a drug coating of a drug balloon by using modeling software, and importing a print file of the three-dimensional model into a printer;
and 2, adding the printing material of the medicine coating into the printer, and printing out a first medicine coating according to the printing file.
2. The method of manufacturing a drug balloon according to claim 1, wherein step 2 is printed using 3D printing technology.
3. The method of manufacturing a drug balloon according to claim 2, wherein the 3D printing technique comprises at least a fused deposition modeling technique.
4. The method of making a drug balloon of claim 1, further comprising attaching a fixation balloon body to the first drug coating.
5. The method of making a drug balloon of claim 4, wherein the lower surface of the first drug coating wraps around the outer surface of the balloon body.
6. The method of making a drug balloon of claim 1, wherein the printed material of the drug coating comprises an active drug and a carrier.
7. The method for preparing a drug balloon according to claim 6, wherein the carrier at least comprises one or more of inorganic salts and polyols.
8. A drug balloon obtained by the method for manufacturing a drug balloon according to any one of claims 1 to 7.
9. The drug balloon obtained by the preparation method of the drug balloon according to claim 8, wherein the first drug coating layer of the drug balloon comprises a first substrate, the lower surface of the first substrate is connected with the outer surface of the balloon body, and the upper surface of the first substrate has a protruding structure.
10. Use of a drug balloon according to any of claims 8-9 for the treatment of stenosis or restenosis within a blood vessel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011609609.0A CN112618922A (en) | 2020-12-30 | 2020-12-30 | Preparation method of drug balloon, prepared drug balloon and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011609609.0A CN112618922A (en) | 2020-12-30 | 2020-12-30 | Preparation method of drug balloon, prepared drug balloon and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112618922A true CN112618922A (en) | 2021-04-09 |
Family
ID=75286599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011609609.0A Pending CN112618922A (en) | 2020-12-30 | 2020-12-30 | Preparation method of drug balloon, prepared drug balloon and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112618922A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113427784A (en) * | 2021-06-29 | 2021-09-24 | 伊索曼(中山)医疗器械有限公司 | Manufacturing method of medical balloon surface bulge and medical balloon |
| CN114010917A (en) * | 2021-11-05 | 2022-02-08 | 广东博迈医疗科技股份有限公司 | Double-medicine administration balloon |
| CN114470341A (en) * | 2022-03-02 | 2022-05-13 | 南京鼓楼医院 | Composite microneedle balloon and preparation method thereof |
| CN114504723A (en) * | 2021-12-22 | 2022-05-17 | 融冲(深圳)生物医疗科技有限责任公司 | Polymer balloon and preparation method thereof |
| CN115054811A (en) * | 2022-08-18 | 2022-09-16 | 山东瑞安泰医疗技术有限公司 | Medicine balloon catheter device capable of forming endogenous vascular stent |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050015046A1 (en) * | 2003-07-18 | 2005-01-20 | Scimed Life Systems, Inc. | Medical devices and processes for preparing same |
| US20080299290A1 (en) * | 2004-08-16 | 2008-12-04 | Functional Microstructures Limited | Method of Producing a Microneedle or Microimplant |
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| CN106109245A (en) * | 2016-08-16 | 2016-11-16 | 华南农业大学 | Cancer therapy drug that a kind of 3D of employing printing technique prepares and method |
| CN106798951A (en) * | 2017-02-24 | 2017-06-06 | 浙江巴泰医疗科技有限公司 | A kind of preparation method of medicament elution sacculus |
| CN107427670A (en) * | 2014-12-29 | 2017-12-01 | 波士顿科学国际有限公司 | Composition, apparatus and method for the multistage release of chemotherapeutics |
| CN108348734A (en) * | 2015-09-17 | 2018-07-31 | 开金血管有限公司 | The wedge-shaped cutter of medical balloon |
| CN109125912A (en) * | 2018-08-09 | 2019-01-04 | 武汉大学 | A kind of 3D printing microneedle patch and preparation method thereof that Intelligent blood sugar is adjusted |
| CN111298274A (en) * | 2020-05-14 | 2020-06-19 | 上海脉全医疗器械有限公司 | Medicine balloon and using method thereof |
-
2020
- 2020-12-30 CN CN202011609609.0A patent/CN112618922A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050015046A1 (en) * | 2003-07-18 | 2005-01-20 | Scimed Life Systems, Inc. | Medical devices and processes for preparing same |
| US20080299290A1 (en) * | 2004-08-16 | 2008-12-04 | Functional Microstructures Limited | Method of Producing a Microneedle or Microimplant |
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| CN107427670A (en) * | 2014-12-29 | 2017-12-01 | 波士顿科学国际有限公司 | Composition, apparatus and method for the multistage release of chemotherapeutics |
| CN108348734A (en) * | 2015-09-17 | 2018-07-31 | 开金血管有限公司 | The wedge-shaped cutter of medical balloon |
| CN106109245A (en) * | 2016-08-16 | 2016-11-16 | 华南农业大学 | Cancer therapy drug that a kind of 3D of employing printing technique prepares and method |
| CN106798951A (en) * | 2017-02-24 | 2017-06-06 | 浙江巴泰医疗科技有限公司 | A kind of preparation method of medicament elution sacculus |
| CN109125912A (en) * | 2018-08-09 | 2019-01-04 | 武汉大学 | A kind of 3D printing microneedle patch and preparation method thereof that Intelligent blood sugar is adjusted |
| CN111298274A (en) * | 2020-05-14 | 2020-06-19 | 上海脉全医疗器械有限公司 | Medicine balloon and using method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113427784A (en) * | 2021-06-29 | 2021-09-24 | 伊索曼(中山)医疗器械有限公司 | Manufacturing method of medical balloon surface bulge and medical balloon |
| CN113427784B (en) * | 2021-06-29 | 2022-09-13 | 伊索曼(中山)医疗器械有限公司 | Manufacturing method of medical balloon surface bulge and medical balloon |
| CN114010917A (en) * | 2021-11-05 | 2022-02-08 | 广东博迈医疗科技股份有限公司 | Double-medicine administration balloon |
| CN114504723A (en) * | 2021-12-22 | 2022-05-17 | 融冲(深圳)生物医疗科技有限责任公司 | Polymer balloon and preparation method thereof |
| CN114470341A (en) * | 2022-03-02 | 2022-05-13 | 南京鼓楼医院 | Composite microneedle balloon and preparation method thereof |
| CN115054811A (en) * | 2022-08-18 | 2022-09-16 | 山东瑞安泰医疗技术有限公司 | Medicine balloon catheter device capable of forming endogenous vascular stent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112618922A (en) | Preparation method of drug balloon, prepared drug balloon and application thereof | |
| US11357623B2 (en) | Decalcifying heart valve | |
| JP4727987B2 (en) | Coated medical devices | |
| US6203551B1 (en) | Chamber for applying therapeutic substances to an implant device | |
| US6379381B1 (en) | Porous prosthesis and a method of depositing substances into the pores | |
| US6287628B1 (en) | Porous prosthesis and a method of depositing substances into the pores | |
| US20050245905A1 (en) | Local drug-delivery system | |
| US20030064965A1 (en) | Method of delivering drugs to a tissue using drug-coated medical devices | |
| US20050147644A1 (en) | Reduced restenosis drug containing stents | |
| US20020128704A1 (en) | Stent and method for drug delivery from stents | |
| CN101909687B (en) | Methods for incorporating drug into elastomeric medical device related applications | |
| WO2002026162A2 (en) | A method of loading a substance onto an implantable device | |
| WO2016173553A1 (en) | Support and drug delivery device | |
| CN101909668B (en) | Ordered coatings for drug eluting stents and medical devices | |
| WO2009144580A2 (en) | Coatings for promoting endothelization of medical devices | |
| WO2001017577A1 (en) | A porous prosthesis and a method of depositing substances into the pores | |
| BRPI0717442B1 (en) | Method for producing a stent to reduce the occurrence and / or extent of restenosis or thrombosis and expandable stent | |
| WO2009023500A1 (en) | Drug delivery device, compositions and methods relating thereto | |
| CN107376030B (en) | Preparation method of drug balloon, prepared drug balloon and application thereof | |
| CN112076380A (en) | Preparation method of drug balloon, prepared drug balloon and application thereof | |
| US20060286141A1 (en) | Systems for gel-based medical implants | |
| CN110584851A (en) | Ultrasonic controlled-release grooved degradable microsphere drug-loaded stent and preparation method thereof | |
| US20090112307A1 (en) | Stent having a base body of a bioinert metallic implant material | |
| EP1885345A1 (en) | Thin foam coating comprising discrete, closed-cell capsules | |
| US20100057219A1 (en) | Device surface design for better cell adhesion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |